Overview

Sub-Q Versus IV Furosemide in Acute Heart Failure

Status:
Completed

Trial end date:
2017-07-01

Target enrollment:

Participant gender:

Summary

This study evaluates the clinical efficacy of subcutaneously administered Furosemide Injection Solution versus intravenous administration of Furosemide Injection, United States Pharmacopeia (USP) in adult patients presenting to a heart failure clinic with decompensated heart failure. Half of the patients will receive a subcutaneously administered Furosemide Injection Solution; the other half will receive an intravenous administration of Furosemide Injection.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

Johns Hopkins University

Collaborator:

scPharmaceuticals, Inc.

Treatments:

Furosemide
Pharmaceutical Solutions